Full Breakdown
WHO Prequalifies First Infant Malaria Treatment
4/25/2026, 10:10:27 AM
Core Event: WHO Grants Prequalification to Artemether-Lumefantrine for Infants Under 5 kg
On 24 April 2024, the World Health Organization (WHO) announced the prequalification of a fixed-dose combination of artemether and lumefantrine for newborns and infants weighing less than 5 kilograms (2.2 lb). This is the first antimalarial formulation specifically designed for the youngest patients, allowing national health authorities to adopt the medicine even where full clinical trials are not feasible.
Background & Context: Malaria Burden and Treatment Gap for Newborns
Children under five account for roughly two-thirds of global malaria deaths, and infants under six months are especially vulnerable. In 2024, malaria caused an estimated 282 million cases and more than 500 000 deaths worldwide, with sub-Saharan Africa responsible for nine-tenths of both cases and fatalities. Historically, infants have been treated with pediatric formulations intended for older children, exposing them to dosing errors and toxicity. The lack of an infant-appropriate drug has been identified as a critical gap in malaria control strategies.
Key Figures & Organizations
- World Health Organization (WHO) – the United Nations agency responsible for global health standards and the prequalification process.
- Tedros Adhanom Ghebreyesus – Director-General of WHO, who presented the announcement.
- UN agencies – ready to procure and distribute the medicine in endemic regions once governments grant approval.
Data & Statistics
- Approximately 30 million infants are born each year in malaria-endemic areas across Africa.
- Since 2000, global malaria interventions have averted an estimated 14 million deaths.
- Annual malaria-related maternal impact includes ~10 000 maternal deaths, 200 000 stillbirths and 550 000 low-birth-weight infants.
- The new formulation targets babies under 5 kg, a population representing a substantial share of the disease burden.
Why It Matters: Closing a Critical Care Gap
Prequalification enables countries to approve the medicine without conducting their own large-scale trials, accelerating access. It also authorizes UN agencies to procure and distribute the treatment, subject to national endorsement. By providing a dosage-accurate formulation, the drug reduces the risk of under- or overdosing, a known contributor to infant mortality. The approval complements recent WHO actions, including the prequalification of three rapid diagnostic tests and the rollout of the RTS,S malaria vaccine in multiple African nations.
Official Statements & Responses
WHO’s statement emphasized that the prequalification confirms the product meets international standards for quality, safety, and efficacy. Tedros highlighted a broader shift in malaria control, noting that new vaccines, diagnostics, next-generation mosquito nets and now infant-specific medicines are collectively turning the tide against the disease. UN agencies have indicated readiness to incorporate the treatment into existing procurement mechanisms once governments approve it.
Verbatim Quotes
- “The prequalification designation indicates that the medicine meets international standards of quality, safety and efficacy,” — WHO statement
- “For centuries, malaria has stolen children from their parents, and health, wealth and hope from communities,” — Tedros Adhanom Ghebreyesus, WHO chief
- “But today, the story is changing. New vaccines, diagnostic tests, next-generation mosquito nets and effective medicines, including those adapted for the youngest, are helping to turn the tide.” — Tedros Adhanom Ghebreyesus, WHO chief
- “The WHO approval allows countries to authorize the drug even if they lack the capacity to conduct full clinical trials.” — WHO statement
- “The approval also enables UN agencies to procure and distribute the treatment in malaria-endemic areas, subject to government approval.” — WHO statement
What’s Next: Implementation and Monitoring
National malaria programmes are expected to integrate the infant formulation into treatment guidelines during 2024-2025. UN procurement channels will begin bulk purchases pending governmental clearance. WHO will monitor safety and effectiveness through its surveillance networks, with periodic reviews to assess impact on infant mortality in high-burden settings.
